NCT06091124 (NEOBLAST) is a Phase 2 clinical trial of Adebrelimab in Neuroendocrine Carcinoma of the Bladder, sponsored by RenJi Hospital.

Who is sponsoring NCT06091124?

NCT06091124 is sponsored by RenJi Hospital.

What drugs are being tested in NCT06091124?

Interventions in NCT06091124: Adebrelimab, Etoposide, Cisplatin, Radical Cystectomy.

What condition does NCT06091124 study?

NCT06091124 studies Neuroendocrine Carcinoma of the Bladder, Bladder Cancer.

Is NCT06091124 still recruiting?

NCT06091124 is currently recruiting now. Last updated 8 December 2025.

Last reviewed 2025-12-08 · How we verify

NCT06091124: NEOBLAST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma

Recruiting now Phase 2 Last updated 8 December 2025

What this trial tests

Phase 2 trial testing Adebrelimab in Neuroendocrine Carcinoma of the Bladder in 22 participants. Currently enrolling.

Timeline

16 November 2023

Primary endpoint
1 January 2027

31 December 2027

Quick facts

Lead sponsor	RenJi Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	16 November 2023
Primary completion	1 January 2027
Estimated completion	31 December 2027
Sites	5 locations across China

Drugs / interventions tested

Adebrelimab — full drug profile →
Etoposide (etoposide) — full drug profile →
Cisplatin (cisplatin) — full drug profile →
Radical Cystectomy

Conditions studied

Neuroendocrine Carcinoma of the Bladder — all drugs for Neuroendocrine Carcinoma of the Bladder →
Bladder Cancer — all drugs for Bladder Cancer →

Sponsor

RenJi Hospital

Who can join

Adults 18 to 75, any sex, with Neuroendocrine Carcinoma of the Bladder or Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn about the efficacy and safety of neoadjuvant adebrelimab plus etoposide and cisplatin in patients with neuroendocrine bladder carcinoma. The main questions it aims to answer are: * The pathologic complete response rate at radical cystectomy * Safety and tolerability of combination therapy Participants will be treated with a combination therapy of adebrelimab, etoposide, and cisplatin before radical cystectomy, with a maximum of 4 cycles.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Small cell carcinoma of the bladder: Review of pathogenesis, presentation, and management.
Simon NI, Kydd AR, Akbulut D, Takeda D, et al · · 2025 · cited 1× · PMID 40842970 · DOI 10.1177/23523735251370956
Neoadjuvant treatment patterns and biomarker selection in muscle-invasive bladder cancer.
He W, Xie J, Wang Z, Wang M, et al · · 2025 · cited 1× · PMID 40591027 · DOI 10.1007/s12672-025-02796-6
Molecular and immune characteristics of neuroendocrine bladder carcinoma - Implications for diagnosis, prognosis, and therapy: A review.
Zhang T, Zhang X, Qian L, Hu C, et al · · 2025 · PMID 41065174 · DOI 10.17305/bb.2025.13151

Verify or expand the search:

Other trials of Adebrelimab

Trials testing the same drug.

NCT07398560 — Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lu · Phase 2 · not yet recruiting
NCT07392541 — Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer · Phase 1, PHASE2 · recruiting
NCT07266025 — Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-Hi · Phase 2 · not yet recruiting
NCT06177522 — Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07241793 — Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metast · Phase 2 · recruiting

Other RenJi Hospital trials

Trials by the same sponsor.

NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06091124 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
Last refreshed: 8 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06091124.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing